Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on
 renal function and perfusion in 16 healthy subjects.
Analysis of the effect of i.v. VAS203 on renal function and perfusion in healthy subjects.

 Primary objective:

 Possible adverse effect of VAS203 on the Renal Plasma Flow (RPF) and the Glomerular
 Filtration Rate (GFR) during and after 6 hours of constant-rate iv. infusion of 10 mg/kg
 VAS203.

 Secondary objective:

 To analyse the effects of VAS203 on

 -  filtration fraction

 -  hemodynamics (afferent and efferent resistance, intraglomerular pressure)

 -  markers of kidney injury and renal function

 -  systolic, mean and diastolic brachial blood pressure

 -  Plasma Pharmacokinetic of VAS203 and its first metabolite.
Inclusion Criteria:

 1. Informed consent in writing available.

 2. Willing and able to comply with all requirements of the study.

 3. Male, 18 and 45 years (inclusive).

 4. Subject has a body weight between 60 kg and 100 kg, extremes included.

 5. BMI 18 to 27 kg/m2.

 6. Non-smoker

 7. Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance > 90
 ml/min

 8. Good general health as judged by the Investigator, as determined by medical history,
 physical examination, vital signs (systolic and diastolic blood pressure and pulse
 rate) and clinical laboratory parameters (clinical chemistry, hematology, and
 urinalysis)

 Exclusion Criteria:

 1. Clinically significant abnormalities in physical examination, vital signs or clinical
 laboratory parameters (according to the Investigator's judgment).

 2. Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase > 2-times
 above the upper limit of normal range.

 3. Subject with Cockcroft-Gault clearance < 90 ml/min.

 4. Clinically significant history of cardiovascular disease or any known present
 cardiovascular disease.

 5. History of clinically significant neurological, gastrointestinal, renal, hepatic,
 psychological, pulmonary, metabolic, endocrine, hematological, or other major
 disorders.

 6. Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.

 7. Office heart rate at screening after at least 5 minutes outside the range of 50- 99
 beats per minute (inclusive).

 8. Concomitant use of OTC medication within 1 week prior to dosing, except use of
 paracetamol (up to 2 g/day).

 9. Participation in any other clinical study within 30 days prior to inclusion in this -